Those patients taking Rosuvastatin and RVX-208 had a highly statistically significant Percent Atheroma Volume (PAV) plaque regression of -1.43% with probability value of p<0.002.

Similar results were seen at follow-up. There was regression of coronary atheroma as measured by change in PAV for patients with and without diabetes (−0.83 ± 0.13 vs. −1.15 ± 0.13%; P = 0.08).

On multivariate analysis, percent change in HDL-C was found to be an independent predictor of change in PAV and total atheroma volume (TAV) (P = .001 and P = .004, respectively).

CARAT is a double-blind, placebo-controlled Phase II study designed to assess the impact of CER-001 on the regression of atherosclerotic plaque in post-ACS patients by measuring the percent ...

CARAT is a double blind, placebo-controlled, phase II study intending to assess the impact of CER-001 on the regression of atherosclerotic plaque in post-ACS patients by measuring PAV using ...

The notion of plaque reduction, known medically as regression of atherosclerosis, arose from a fortuitous observation during World War II. Norwegian scientists noticed that the scarcity of food ...

Baseline plaque area is over 3.4 times more powerful than a Framingham risk equation, in the sense that after adjustment in multiple regression for more variables than in Framingham, patients with ...

Baseline intravascular ultrasonography was used to identify a target artery for imaging with the primary endpoint of the study being percent atheroma volume (PAV), and a secondary outcome being ...

The primary efficacy measure, change in PAV, increased 0.73 percent in the glimepiride group and decreased 0.16 percent in the pioglitazone group.

“About 78.1% showed regression of atherosclerosis in the most severely diseased 10mm segment of the coronary artery”, in other words, the thickest area of the plaque, he explains.